Brook StarRay Wireless Controller Now Available — Native PS5 Support Meets Xbox-Style Control 
OpenWorld (NASDAQ: OPNW) Signs Definitive Merger Agreement to Acquire Blocksight 
Scalare Launches EquityRoom, Adding a Subscription Revenue Stream to Its Founder Ecosystem 
Megaannum Capital and Zhongke Xianxing Venture Capital Enter into Strategic Partnership Monopar Therapeutics Reports Second Quarter 2022 Financial Results and Recent Program Developments
Validive® Phase 2b/3 VOICE Trial Continues Adding Sites in the U.S. and Europe and Enrolling…
aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod (ATYR1923) for Treatment of Pulmonary Sarcoidosis
Company is investigating efzofitimod in global pivotal Phase 3 EFZO-FIT™ study in pulmonary sarcoidosis patients…
89bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update
– Reported positive topline results from ENTRIGUE Phase 2 trial of pegozafermin in severe…
Synthetic Biologics Reports Second Quarter 2022 Operational Highlights and Financial Results
-Prioritizing the advancement of novel oncolytic adenovirus (OV) platform- -Cash balance as of August 1,…
Enzo Biochem to Launch Monkeypox Testing Services this Week
NEW YORK, NY, Aug. 11, 2022 (GLOBE NEWSWIRE) — Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo”…
Surrozen Reports Second Quarter 2022 Financial Results
Phase 1 clinical trials of SZN-1326 and SZN-043 initiated and ongoing Preclinical proof-of-concept data for…
Fortress Biotech Subsidiary Helocyte Announces Grant that Could Provide Over $20 Million from National Institute of Allergy and Infectious Diseases for Phase 2 Study of Triplex for Control of Cytomegalovirus in Patients Undergoing Liver Transplantation
MIAMI, Aug. 11, 2022 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative…
RAPT Therapeutics Reports Second Quarter 2022 Financial Results
Company maintains strong cash position of $207.3 million SOUTH SAN FRANCISCO, Calif., Aug. 11, 2022…
Motus GI Regains Compliance with Nasdaq Minimum Bid Price Requirement
FORT LAUDERDALE, Fla., Aug. 11, 2022 (GLOBE NEWSWIRE) — Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus…
Summit Therapeutics Inc Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2022
Menlo Park, California, Aug. 11, 2022 (GLOBE NEWSWIRE) — Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,”…
Vaxxinity Reports Second Quarter 2022 Financial Results and Provides Corporate Updates
• UB-612 Phase 3 COVID-19 Heterologous Boost Trial on Track for Topline Readout in Fourth…
Century Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates
– Following the recent submission of the IND application for CNTY-101 and pending FDA clearance,…
Ikena Oncology Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
Advancement across Company’s pipeline towards regulatory and data milestones BOSTON, Aug. 11, 2022 (GLOBE NEWSWIRE)…
Better Choice Company Reports Record Second Quarter 2022 Gross Sales and Provides Corporate Update
Better Choice Reports Record Second Quarter 2022 Gross Sales of $19.8 Million and Net Sales…
Abeona Therapeutics Reports Second Quarter 2022 Financial Results
Disposition of MPS programs allows Abeona to extend runway of current cash into 2Q 2023…
Verrica Pharmaceuticals Reports Second Quarter 2022 Financial Results
Verrica held Type A meeting with the FDA regarding the path forward for the resubmission…
Innovation1 Biotech Appoints Chief Scientific Officer Andrew L. Salzman, M.D. to its Board of Directors
NEW YORK, Aug. 11, 2022 (GLOBE NEWSWIRE) — Innovation1 Biotech Inc. (OTCQB: IVBT) (“Innovation1” or…
Wave Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update
WVE-006 announced as investigational development candidate for AATD with CTA submissions expected in 2023; first-in-class RNA…
CorMedix Inc. Reports Second Quarter and Six Month 2022 Financial Results and Provides Business Update
Conference Call Scheduled for Today at 8:30 a.m. Eastern Time BERKELEY HEIGHTS, N.J., Aug. 11,…
Aleafia Health Announces $12.0 Million Total Net Revenue in First Quarter, Representing a 13% Increase Over the Prior Year
31% increase in branded cannabis net revenue1 to $10.0 million from $7.6 million in the…